GIVAUDAN N/ CH0010645932 /
| 14/05/2024 17:30:46 | Var. -38.00 | Volume | Denaro21:38:21 | Lettera21:38:21 | Capitalizzazione di mercato | Dividend Y. | Rapporto P/E |
|---|---|---|---|---|---|---|---|
| 4,066.00CHF | -0.93% | 18,160 Fatturato: 73.75 mill. |
4,030.00Quantità in denaro: 15 | 3,984.00Quantità in lettera: 1 | 37.54 bill.CHF | 1.67% | 42.00 |
Descrizione business
Givaudan is a global leading company in taste and wellbeing, and fragrance and beauty. With its heritage stretching back over 250 years, the Company has a long history of innovating scents and tastes. From a favourite drink to your daily meal, from prestige perfumes to cosmetics and laundry care, its creations inspire emotions and delight millions of consumers the world over. The Company is committed to driving purpose-led, long-term growth while leading the way to improve happiness and health for people and nature.
Consiglio di amministrazione & Consiglio di sorveglianza
| CEO |
|---|
| Gilles Andrier |
| Consiglio di amministrazione |
| Tom Hallam, Anne Tayac, Louie D’Amico, Maurizio Volpi, Simon Halle-Smith, Willem Mutsaerts |
| Consiglio di sorveglianza |
| Calvin Grieder, Ingrid Deltenre, Olivier Filliol, Sophie Gasperment, Victor Balli, Tom Knutzen, Roberto Guidetti |
Dati aziendali
| Name: | Givaudan SA |
| Indirizzo: | 5, Chemin de la Parfumerie,Vernier |
| Telefono: | +41-22-780-9111 |
| Fax: | +41-22-780-9150 |
| E-mail: | global.recruitment@...dan.com global.recruitment@givaudan.com |
| Internet: | www.givaudan.com |
| Industria: | Commodities |
| Settore: | Chemicals |
| Sub settore: | - |
| Fine dell'anno finanziario: | 31/12 |
| Flottante libero: | 48.91% |
| Data dell'IPO: | 08/06/2000 |
Rapporti con gli investitori
| Name: | Claudia Pedretti |
| IR telefono: | +41 22 7809111 |
| IR Fax: | +41-22-780-9090 |
| IR e-mail: | givaudan.investors@g...dan.com givaudan.investors@givaudan.com |
Principali azionisti
| Altri | 78.07% | |
| William H Gates III and Melinda Grench Gates | 13.86% | |
| BlackRock Inc | 5.06% | |
| MFS Investment Management | 3.01% |
